Postpartum Hemorrhage Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Postpartum Hemorrhage Treatment Market By Drug Type (Oxytocin, Prostaglandins (Dinoprostone, Misoprostol), Ergot Alkaloids (Ergometrine, Methyl Ergonovine), Tranexamic acid, Pabal, Carboprost, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Postpartum Hemorrhage Treatment Market size was valued at USD 802.34 in 2021, growing at a CAGR of 5.3% during the forecast period 2022-28. The Postpartum Hemorrhage (PPH) is an obstetric hemorrhagic condition that is a prime reason for maternal mortality. In postpartum hemorrhagic condition patient loss about 500mL blood in vaginal delivery or approximately 1000mL blood after cesarean delivery. It is categorized into two types namely, primary postpartum hemorrhage and secondary postpartum hemorrhage. Most commonly used drugs in postpartum hemorrhage are oxytocin and misoprostol. Rise in prevalence of multiple pregnancies, inverted uterus, and other pregnancy complication, increase in risk factors for postpartum hemorrhage such as uterine atony, rise in R&D for the innovation of newer drugs, product pipeline of postpartum hemorrhage drugs, and rise in anemia in pregnant woman are anticipated to fuel the postpartum hemorrhage treatment market. However, adverse effects associated with drugs, stringent regulatory guidelines for newer drug approval, and lack of awareness about drugs in underdeveloped countries may impede the growth of postpartum hemorrhage treatment market.

Postpartum Hemorrhage Treatment Market

MARKET SUMMARY
-
5.3%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 5.3%
  • Largest Market– Europe
  • Fastest Growing Market– North America

Postpartum Hemorrhage Treatment Market

  • The report on global postpartum hemorrhage treatment market gives historical, current and future market sizes (US$ Bn) based on drug type, route of administration, distribution channel and region.
  • postpartum hemorrhage treatment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Novartis AG
  • Fresenius Kabi AG
  • Pfizer, Inc.
  • GlaxoSmithKline Plc
  • Ferring B.V.
  • Cipla Inc.
Postpartum Hemorrhage Treatment Market

Drivers And Restraints

Drivers: The Support from healthcare organizations, Rising pregnancy complications.
Restraints: Dearth of trained healthcare providers, High cost of the devices.


North-America got significant share

Postpartum Hemorrhage Treatment Market

Geographically, global postpartum hemorrhage treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa regions. North America is growth attributed to high awareness about postpartum hemorrhage drugs among physicians, better availability of products, and increase in healthcare expenditure. Europe is poised to grow due to increase in complicated pregnancy cases such as severe preeclampsia, high existence of anemia in pregnant women, and high awareness about postpartum hemorrhage treatment among healthcare professionals. Asia Pacific has a significant share, which is attributed to increase in number of childbirths in India and China, rise in prevalence of postpartum hemorrhage in South Korea, and rise in R&D activities for the innovation of newer drugs. Latin America expected to account for notable share owing to rise in pre-mature labors in Brazil. Middle East and Africa growth driven by rise in prevalence of postpartum hemorrhage cases due to malnutrition in pregnant women, multiple gestations in Saudi Arabia women are expected to boost the market in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Postpartum Hemorrhage Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Novartis AG (Switzerland)
  • Fresenius Kabi AG (Germany)
  • Pfizer, Inc. (U.S.)
  • GlaxoSmithKline Plc (U.K.)
  • Ferring B.V. (Switzerland)
  • Cipla Inc. (India)

Description

Postpartum Hemorrhage Treatment Market size was valued at USD 802.34 in 2021, growing at a CAGR of 5.3% during the forecast period 2022-28. The Postpartum Hemorrhage (PPH) is an obstetric hemorrhagic condition that is a prime reason for maternal mortality. In postpartum hemorrhagic condition patient loss about 500mL blood in vaginal delivery or approximately 1000mL blood after cesarean delivery. It is categorized into two types namely, primary postpartum hemorrhage and secondary postpartum hemorrhage. Most commonly used drugs in postpartum hemorrhage are oxytocin and misoprostol. Rise in prevalence of multiple pregnancies, inverted uterus, and other pregnancy complication, increase in risk factors for postpartum hemorrhage such as uterine atony, rise in R&D for the innovation of newer drugs, product pipeline of postpartum hemorrhage drugs, and rise in anemia in pregnant woman are anticipated to fuel the postpartum hemorrhage treatment market. However, adverse effects associated with drugs, stringent regulatory guidelines for newer drug approval, and lack of awareness about drugs in underdeveloped countries may impede the growth of postpartum hemorrhage treatment market.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX